Green Leaf Pharmaceutical: New pharmaceuticals used in Phase III clinical trials used to treat Parkinson's Phase III clinical trial reached the preset end

On July 20, 2022, Green Leaf Pharmaceutical (02186.HK) opened nearly 7%in the early early trading. As of, the increase was 4.53%at HK $ 2.54, and the latest market value was HK $ 9.016 billion.

On the news, the company announced yesterday that the group's research on the new drug in the research of the new drug in the injection of the Chinese Phase III clinical trials that the Parkinson's disease was treated with Parkinson's disease reached the preset end. The study is a multi -centered, random, double -blind, and placebo -controlled research, which verifies the effectiveness and safety of LY03003 to treat early Parkinson's disease. A total of 294 patients with early primary Parkinson were incorporated in the test, and they randomly entered the LY03003 group or placebo group at a ratio of 1: 1.

The test results showed that compared with the placebo group, the LY03003 group unified Parkinson's disease scoring component (UPDRS) II+III scores improved significantly compared with the baseline, and the differences between the two groups were statistically significant (P <0.001). The two groups of relevant secondary evaluation indicators also have statistically significant significance (P <0.001). In terms of safety, LY03003 has good overall safety tolerance and has not occurred serious adverse events related to test drugs.

The above results show that LY03003 treats early primary Parkinson's disease is safe and effective, which can comprehensively improve the symptoms of Parkinson's disease movement.

According to the information, LY03003 is one of the key central nervous system developed by the group head of the leader of the group leader. The drug is currently developing simultaneously in the Chinese, the United States, Europe and Japan. The group plans to register and list LY03003 in China, the United States, Japan, Europe, and other countries. At the same time, the group is also developing a mito -release micro -ball for the injection of the administration of January in January. According to the company, based on the huge demand of Parkinson's disease, LY03003 will have a good market prospect in the future and will enrich the group's future product portfolio.

At the same time, the Group has listed in the field of central nervous system therapy fields, including injection of Lipbarone micro -ball (II) (Ruixinbao ®), Roman sulfur sulfur tablets (Sirikang®) and Foga acid sulfur sulfur sulfur sulfur sulfur sulfur Slow -release tablets, Lith's bright leather patch, and Lith's Ming Duo -ray skin, fentini -transparent patch, Dingnnorphine -transparent skin, covering China, the United States, Europe, and and Japan's large pharmaceutical markets and rapid development of emerging markets in more than 80 countries and regions around the world.

In addition, the group stated that there are many research projects in Chinese and overseas markets, covering a variety of diseases such as depression and Parkinson's disease, and formed a rich product portfolio in the field of central nervous treatment.

- END -